Genzyme Molecular doubles after tumor news - 500 Beiträge pro Seite

[jen]

Genzyme Molecular <GZMO.O> higher after tumor news

BOSTON, Aug 17 (Reuters) - Shares in Genzyme Molecular Oncology <GZMO.O> roared higher on Thursday after the company
said its proprietary technology had been used to identify dozens of new genes involved in the process tumors use to feed themselves.

The development offers many potential new targets for cancer therapy concentrating on how tumors grow blood vessels to feed
themselves.

The shares were up 3-3/8 at 11-1/8 in active, late afternoon trading. On Wednesday, they closed at 7-12/16.

The research used a technology developed by scientists at Johns Hopkins University in Baltimore and licensed exclusively to Genzyme
Molecular Oncology called Serial Analysis of Gene Expression (SAGE). It was used to identify 79 genes that behave differently in
tumor vessels than they do in normal blood vessels.

The process of building new blood vessels, called angiogenesis, is new in cancer research. Several new drugs are being tested that are
aimed at starving tumors by choking off their blood supply.

SAGE helps identify the active genes in a tissue sample. Most cells contain all the genes that a person has, but sometimes they are
expressed, or turned on, and sometimes they are not, depending on the cell type.

Identifying these genes, the object of current research at both Johns Hopkins and Genzyme, would allow scientists to figure out
whether they can be targeted to inhibit angiogenesis.

((Christopher Noble, Boston newsroom, 617-367-4106; fax [phone]; e-mail [e-mail]))


Gruss,
jen

[jen]

Es gibt ja bislang wenig Resonanz auf die News von GZMO in Deutschland. Wäre schön, wenn irgendjemand
mit Fach- und Sachverstand zu den neuen Erkenntnissen Stellung nehmen könnte.
Bis jetzt hat der 100%-ige Kursanstieg ja gerade mal die Verluste der letzten Wochen egalisiert.
Fast war ich so weit, das Hanttuch zu werfen und zu verkaufen.
Wie geht es weiter?
GZMO befindet sich finanziell in einer äusserst angespannten Situation. Wir sich das neue Wissen bald in
barer Münze auszahlen? -durch Kooperationen?, -Lizenzen?, -kann die Entdeckung der Gene und deren
Einfluss auf die Tumorzellen patentiert werden?? Fragen, die vielleicht Du beantworten kannst, HRDUERR?

Gruss,
jen

[Mate972]

Vorbörslich schaut es gut aus, Gzmo hat noch mal gute 15% nachgelegt!

der Biotech-Sektor hat sich allg. in den letzten Wochen etwas erholt. Jetzt könnte es wieder aufwärtsgehen. Hier ein Bericht:


Announcements lift biotech shares

By Ted Griffith, CBS.MarketWatch.com
Last Update: 6:14 PM ET Aug 17, 2000 NewsWatch
Latest headlines

NEW YORK (CBS.MW) - Led by shares of Genzyme Molecular Oncology and Incyte Genomics, biotechnology stocks pushed higher Thursday.

The Amex Biotechnology Index ($BTK: news, msgs) rose 3.1 percent and the Nasdaq Biotechnology Index ($IXBT: news, msgs) added 2.3 percent. Thursday`s gains in biotech shares broke a streak of losses over the previous three days.

Shares of Genzyme Molecular Oncology (GZMO: news, msgs) rocketed 68 percent higher after the unit of Genzyme Corp. said it had the rights to new research that could be valuable in developing cancer treatments. The research, performed at Johns Hopkins University, identified genes implicated in tumor blood vessel growth. Scientists hope eventually to be able to starve cancerous tumors by cutting off the blood vessel growth that feeds the tumors, a technique known as anti-angiogenesis.

Shares of Framingham, Mass.-based Genzyme Molecular Oncology rose 5 9/32 to 13 1/32. See full story.

Shares of Incyte Genomics surged 28 percent Thursday after the Palo Alto, Calif.-based company said Motorola licensed Incyte`s gene sequence databases and gene patent portfolio.

Motorola intends to use the databases and gene patent portfolio for technology known as bioarrays. The bioarrays will be part of a Motorola system that is expected to be able to simultaneously monitor the activity of thousands of genes in a given tissue sample.

Shares of Incyte added 19 7/8 to 88 13/16. Shares of Motorola (MOT: news, msgs) gained 1/4 to 36 11/16.

Biogen shares rose after the Cambridge, Mass.- based biotechnology company said it would collaborate with Elan Corp. (ELN: news, msgs) on an experimental drug for the treatment for multiple sclerosis and Crohn`s disease. The drug, called Antegren, showed promise in tests on patients suffering from multiple sclerosis, PaineWebber analyst Elise Wang wrote in a research note.

Biogen already sells a multiple sclerosis treatment called Avonex.

"In our opinion, we believe Antegren may offer a complementary treatment to Avonex in the treatment of MS patients and that it will expand the market franchise for Biogen," Wang wrote.

Biogen (BGEN: news, msgs) shares were up 1/4 to 70 1/2. Shares of Elan, an Irish pharmaceutical company, jumped 5 7/8 to 59 7/8, a 52-week high.